Information
-
Trademark
-
97187298
-
International Classifications
-
Filing Date
December 23, 2021
3 years ago
-
Transaction Date
April 12, 2024
8 months ago
-
Status Date
April 11, 2024
9 months ago
-
Published for Opposition Date
August 22, 2023
a year ago
-
Location Date
October 17, 2023
a year ago
-
First Use Anywhere Date
March 15, 2021
3 years ago
-
First Use In Commerce Date
March 15, 2021
3 years ago
-
Status Code
730
-
Current Location
INTENT TO USE SECTION
Employee Name
MACFARLANE, JAMES W
-
Attorney Docket Number
S21802000100
Attorney Name
Christina M. Licursi
Law Office Assigned Location Code
L40
-
Owners
Mark Drawing Code
3000
Mark Identification
S
Case File Statements
- DM0000: The mark consists of a stylized S in the shape of a swan's wing.
- GS0051: Therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene inhibition therapy and/or RNA interference (RNAi), for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapy, namely, gene augmentation therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; therapeutic pharmaceutical compositions comprised of adeno-associated viral (AAV) vectors and recombinant adeno-associated viral (rAAV) vectors for therapeutic effect in gene therapies using intrathecal administration, for the treatment of genetic diseases and disorders and neurological diseases and disorders; biologic preparations for use in the treatment of genetically based diseases and disorders; biologic preparations for medical purposes, namely, for gene therapy for treating genetic disorders; pharmaceutical preparations that modulate RNA expression for the treatment of neurological diseases and disorders, genetic diseases and disorders, and for the regulation of protein production; gene therapy products, namely, gene delivery pharmaceuticals for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical preparations for gene therapy, gene inhibition and gene augmentation, for the treatment of genetic diseases and disorders and neurological diseases and disorders; viruses, viral vectors and viral constructs, all in the nature of pharmaceutical preparations, for the treatment of neurological diseases and disorders and genetic diseases and disorders; pharmaceutical preparations for gene therapy, for the treatment of genetic diseases and disorders and neurological diseases and disorders; pharmaceutical and biopharmaceutical agents for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, nucleic acid therapeutics for the treatment of genetic disorders and neurological diseases and disorders; pharmaceutical preparations, namely, DNA and/or RNA therapeutics for the treatment of genetic disorders and neurological diseases and disorders
- GS0421: Development of pharmaceutical preparations for use in gene therapy; genetic engineering and biotechnology research; research and development of new products in the field of gene therapeutics; scientific and medical research in the field of genetics, gene therapy and genetic engineering; laboratory research in the fields of genetics, gene therapy, drug development, biotechnology, microbiology and molecular biology; pharmaceutical drug discovery; scientific research in the field of gene therapy discovery; drug development and therapeutic drug development; genetic drug development and therapeutic drug development; biological research; biological drug development and scientific research in the field of biological development
Case File Event Statements
-
4/12/2024 - 8 months ago
24 - NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Type: EXRA
-
4/11/2024 - 9 months ago
23 - SOU EXTENSION 1 GRANTED
Type: EX1G
-
4/11/2024 - 9 months ago
22 - SOU EXTENSION 1 FILED
Type: EXT1
-
4/11/2024 - 9 months ago
21 - SOU TEAS EXTENSION RECEIVED
Type: EEXT
-
10/17/2023 - a year ago
20 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Type: NOAM
-
8/22/2023 - a year ago
19 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Type: NPUB
-
8/22/2023 - a year ago
18 - PUBLISHED FOR OPPOSITION
Type: PUBO
-
8/2/2023 - a year ago
17 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Type: NONP
-
7/19/2023 - a year ago
16 - APPROVED FOR PUB - PRINCIPAL REGISTER
Type: CNSA
-
6/29/2023 - a year ago
15 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
6/29/2023 - a year ago
14 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
6/29/2023 - a year ago
13 - TEAS REQUEST FOR RECONSIDERATION RECEIVED
Type: ERFR
-
5/19/2023 - a year ago
12 - NOTIFICATION OF FINAL REFUSAL EMAILED
Type: GNFN
-
5/19/2023 - a year ago
11 - FINAL REFUSAL E-MAILED
Type: GNFR
-
5/19/2023 - a year ago
10 - FINAL REFUSAL WRITTEN
Type: CNFR
-
4/10/2023 - a year ago
9 - TEAS/EMAIL CORRESPONDENCE ENTERED
Type: TEME
-
4/10/2023 - a year ago
8 - CORRESPONDENCE RECEIVED IN LAW OFFICE
Type: CRFA
-
4/10/2023 - a year ago
7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED
Type: TROA
-
10/12/2022 - 2 years ago
6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED
Type: GNRN
-
10/12/2022 - 2 years ago
5 - NON-FINAL ACTION E-MAILED
Type: GNRT
-
10/12/2022 - 2 years ago
4 - NON-FINAL ACTION WRITTEN
Type: CNRT
-
9/27/2022 - 2 years ago
3 - ASSIGNED TO EXAMINER
Type: DOCK
-
1/15/2022 - 2 years ago
2 - NOTICE OF DESIGN SEARCH CODE E-MAILED
Type: MDSC
-
1/14/2022 - 2 years ago
1 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Type: NWOS